Evidence map›Paper›PMID 35223697›Full record

ArticleFrontiers in pediatrics2022

Protective SARS-CoV-2 Antibody Response in Children With Inflammatory Bowel Disease.

Luca Bosa, Costanza Di Chiara, Paola Gaio, Chiara Cosma, Andrea Padoan, Sandra Cozzani, Giorgio Perilongo, Mario Plebani, Carlo Giaquinto, Daniele Donà and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pediatrics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.4field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Luca BosaUnit of Pediatric Gastroenterology, Digestive Endoscopy, Hepatology and Care of the Child With Liver Transplantation, Department of Women's and Children's Health, University Hospital of Padova, Padova, Italy.
Costanza Di ChiaraPediatric Infectious Diseases, Department of Women's and Children's Health, University Hospital of Padova, Padova, Italy.
Paola GaioUnit of Pediatric Gastroenterology, Digestive Endoscopy, Hepatology and Care of the Child With Liver Transplantation, Department of Women's and Children's Health, University Hospital of Padova, Padova, Italy.
Chiara CosmaDepartment of Laboratory Medicine, University Hospital of Padova, Padova, Italy.
Andrea PadoanDepartment of Laboratory Medicine, University Hospital of Padova, Padova, Italy.
Sandra CozzaniPediatric Infectious Diseases, Department of Women's and Children's Health, University Hospital of Padova, Padova, Italy.
Giorgio PerilongoUnit of Pediatric Gastroenterology, Digestive Endoscopy, Hepatology and Care of the Child With Liver Transplantation, Department of Women's and Children's Health, University Hospital of Padova, Padova, Italy.
Mario PlebaniDepartment of Laboratory Medicine, University Hospital of Padova, Padova, Italy.
Carlo GiaquintoPediatric Infectious Diseases, Department of Women's and Children's Health, University Hospital of Padova, Padova, Italy.
Daniele DonàPediatric Infectious Diseases, Department of Women's and Children's Health, University Hospital of Padova, Padova, Italy.
Mara CananziUnit of Pediatric Gastroenterology, Digestive Endoscopy, Hepatology and Care of the Child With Liver Transplantation, Department of Women's and Children's Health, University Hospital of Padova, Padova, Italy.
University of Padua · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTo date, there's no evidence of an increased risk of SARS-CoV-2 infection or more severe COVID-19 in patients with inflammatory bowel disease (IBD). However, whether COVID-19 alters the clinical course of IBD or whether IBD treatment affects the immunological response to SARS-CoV-2 is still under investigation, especially in children.

aimTo assess the serological response to SARS-CoV-2 in children with IBD, and to evaluate the impact of COVID-19 on the clinical course of IBD. MATERIAL AND

methodsThis prospective study enrolled children (0-18 years) followed-up at the University Hospital of Padova for IBD, who acquired a confirmed SARS-CoV-2 infection between 02.2020 and 02.2021. The anti-SARS-CoV-2 S-RBD IgG titer was evaluated at 3 months after infection and compared to that of a control group of healthy children matched for age, sex, and COVID-19 severity.

resultsTwelve children with IBD ( DISCUSSION: Children with IBD can mount a protective humoral response against SARS-CoV-2, which is comparable to that of their healthy peers regardless of ongoing immunomodulatory treatment. This study also supports the favorable course of PIBD during COVID-19 and vice-versa.

Indexed as

childrenCOVID-19immunological responseinflammatory bowel diseaseneutralizing antibodiespediatricSARS-CoV-2serology

Identifiers

PMID35223697
PMCPMC8866952
OpenAlexW4211014699

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.